At the 2012 ASCO Annual Meeting, Dr. Michael Har-Noy, founder and CEO of Immunovative Therapies, Ltd., presented remarkable survival data a subgroup of HER2+ breast cancer patients.
Dr. Michael Har-Noy states that the immune response resulting from an allogeneic stem cell transplant has been effective in killing resistant metastatic cancer cells despite the tumor's immunoavoidance abilities, but that this immune response is closely linked to the lethal graft versus host disease (GVHD) and is thus of limited clinical use.
Dr. Michael Har-Noy has developed a unique compound, AlloStimTM which was formulated to stimulate a host anti-tumor response while avoiding GVHD toxicity. Dr. Michael Har-Noy describes how AlloStimTM was recently tested in an FDA-approved phase I/II trial involving 42 late-stage metastatic cancer patients with a variety of tumor types. Most patients in the trial experienced prolonged survival and immune-mediated tumor lysis without suffering GVHD toxicity. Conventional RECIST criteria tended to overestimated tumor size, as responding masses swelled and appeared to grow bigger on computed tomographic scan.
Dr. Michael Har-Noy noted that serum interleukin 12 (IL-12) levels were identified to be a consistent predictor of improved survival. Half of the study patients were IL-12 positive and survived a median of 211 days. In contrast, the IL-12 negative subjects lived a median of 131 days. Nine of 16 metastatic breast cancer patients in the study group were IL-12 positive. The HER2+ subset of five breast cancer patients were all IL-12 positive and had a median survival of 416 days, while the median survival of the eleven HER2- patients was only 134 days. Dr. Michael Har-Noy noted that HER2+ tumors metastasize more quickly and have a poorer prognosis then their HER2- counterparts. The remarkable response to AlloStimTM in the HER2+ metastatic breast cancer patients could result from high quantities of anti-HER2+ antibodies exhibited by this patient subset. Dr. Michael Har-Noy adds that the allogeneic cell treatment may augment the ability of these antibodies to destroy the cancer cells.
Please read the abstract on the official ASCO website by clicking here. Dr. Michael Har-Noy is conducting further trials of his unique drugs in Bangkok, Thailand. He is planning a pivotal Phase II/III trial of AlloStimTM in the treatment of refractory breast cancer. For more information, please visit www.immunocare.net.